Clariane (EPA:CLARI) Full Year 2023 Results
Key Financial Results
- Revenue: €5.05b (up 14% from FY 2022).
- Net loss: €49.5m (down by 238% from €35.7m profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Clariane Earnings Insights
Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Healthcare industry in Europe.
Performance of the market in France.
The company's shares are up 7.3% from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for Clariane (2 are significant!) that we have uncovered.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:CLARI
Clariane
Provides a range of medical and non-medical care and support services for the elderly and people with short or longer-term health issues.
Undervalued with moderate growth potential.
